1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 47 results.

$Thumbnail for Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma$

IBCL - 141

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

Javier Munoz

Poster Presenter: Javier Munoz

IBCL - 1414

Racial Disparities in Patients Hospitalized With Follicular Lymphoma. A National Inpatient Retrospective Analysis.

Oscar Borja-Montes

Poster Presenter: Oscar Borja-Montes

Thumbnail for Real-World Inpatient Outcomes Associated With Caplacizumab Use in Immune Thrombotic Thrombocytopenic Purpura: A National Inpatient Sample Analysis

IBCL - 1420

Real-World Inpatient Outcomes Associated With Caplacizumab Use in Immune Thrombotic Thrombocytopenic Purpura: A National Inpatient Sample Analysis

Noorain Ahmad

Poster Presenter: Noorain Ahmad

Thumbnail for Validation of Baseline Total Metabolic Tumor Volume (TMTV) and Total Lesion Glycolysis (TLG) as Predictors of Early Progression (POD24) in Follicular Lymphoma: A Retrospective Study of 100 Patients in Brazil

IBCL - 1459

Validation of Baseline Total Metabolic Tumor Volume (TMTV) and Total Lesion Glycolysis (TLG) as Predictors of Early Progression (POD24) in Follicular Lymphoma: A Retrospective Study of 100 Patients in Brazil

Andre Meireles

Poster Presenter: Andre Meireles

$Thumbnail for Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab (E) With Lenalidomide and Rituximab (R2) in Relapsed/Refractory Follicular Lymphoma (R/R FL)$